2009-02-24 14:31:07 -

Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global biopharmaceutical company, today announced it will release its 2008 fourth quarter and year-end financial results before the market opens on Tuesday, March 3, 2009. The company also said that senior management will host an investor conference call the same day at 8:30 a.m. PT/11:30 a.m. ET to review the company's financial results.

The conference call will be available to interested parties through a live audio webcast at www.abraxisbio.com and www.earnings.com . The call will also be archived and accessible at both sites for six months.


About Abraxis BioScience


Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound chemotherapeutic compound (ABRAXANE), which is based on the company's proprietary tumor targeting technology known as the nabTM platform. The first FDA approved product to use this nabTM platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com.








Investors and Media Inquiries:

Abraxis BioScience, Inc.

Maili Bergman

Director Investor Relations and Corporate Communications

310-405-7522

mbergman@abraxisbio.com

or

PondelWilkinson Inc.

Rob Whetstone

310-279-5963